Kaitlyn D’Onofrio

DocwireNews

Researchers recently tested the&nbsp;effects of omalizumab in patients with systemic lupus erythematosus (SLE) and had positive initial results.&nbsp;Researchers predicted that omalizumab,&nbsp;a monoclonal antibody (mAb) binding immunoglobulin&nbsp;E (IgE),&nbsp;could be beneficial for SLE patients by decreasing the production of type 1 interferon (IFN) through blocking&nbsp;plasmacytoid dendritic cells and basophil activation, they explained.&nbsp;<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
<a href="https://twitter.com/hashtag/NIAMSinTheNews?src=hash&amp;ref_src=twsrc%5Etfw">#NIAMSinTheNews</a> coverage of the research in <a href="https://twitter.com/Rheum_Matters?ref_src=twsrc%5Etfw">@Rheum_Matters</a>: &ldquo;Add-on omalizumab shows potential for SLE.&rdquo; <a href="https://t.co/oxKMzzXOxl">https://t.co/oxKMzzXOxl</a>. <a href="https://t.co/iaIu3iRzmA">https://t.co/iaIu3iRzmA</a>
&mdash; NIAMS (@NIH_NIAMS) <a href="https://twitter.com/NIH_NIAMS/status/1083068431140880385?ref_src=twsrc%5Etfw">January 9, 2019</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>The study included 15 SLE patients with a&nbsp;Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI 2K) of &gt; 4 and elevated autoreactive&nbsp;IgE&nbsp;antibodies. Patients were randomized to receive omalizumab or placebo for 16 weeks; a 16-week open label treatment and four-week washout period followed. Researchers assessed patients&rsquo;&nbsp;SLEDAI 2K, British Isles Lupus Assessment Group index (BILAG 2004), and Physician Global Assessment (PGA)&nbsp;at every visit.&nbsp;<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
Add-on omalizumab shows potential for SLE | <a href="https://t.co/LrBnkYxv0v">https://t.co/LrBnkYxv0v</a>&mdash; Small study but promising for people with <a href="https://twitter.com/hashtag/lupus?src=hash&amp;ref_src=twsrc%5Etfw">#lupus</a> . &#8294;<a href="https://twitter.com/LADAOrg?ref_src=twsrc%5Etfw">@LADAOrg</a>&#8297; &#8294;<a href="https://twitter.com/Looms4Lupus?ref_src=twsrc%5Etfw">@Looms4Lupus</a>&#8297; <a href="https://twitter.com/hashtag/lupuschat?src=hash&amp;ref_src=twsrc%5Etfw">#lupuschat</a> <a href="https://t.co/aOuaiJ3D4Q">https://t.co/aOuaiJ3D4Q</a>
&mdash; Kathleen Arntsen (@KathleenArntsen) <a href="https://twitter.com/KathleenArntsen/status/1080921418093735936?ref_src=twsrc%5Etfw">January 3, 2019</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>By the end of the study, no allergic reactions had occurred in either group;&nbsp;the majority of&nbsp;adverse events were mild.&nbsp;Compared to the placebo group, the omalizumab group showed improved SLEDAI 2K scores at week 16 (P = 0.038) and during the open-label phase in the initial placebo patients (P = 0.020). BILAG scores and PGA did not get worse during the study. Researchers observed a trend in decreased IFN gene signature in omalizumab patients (P = 0.11); IFN gene signature was measured with&nbsp;quantitative&nbsp;polymerase chain reaction.&nbsp;&ldquo;Omalizumab is well tolerated in SLE and associated with improvement in disease activity,&rdquo; the researcher wrote.&nbsp;&ldquo;Larger randomized clinical trials will be needed to assess efficacy of omalizumab in patients with SLE.&rdquo;&nbsp;<a href="https://proddocwire.wpengine.com/abstracts/childhood-systemic-lupus-erythematosus/">Measuring Disease Damage and Its Severity in Childhood-Onset Systemic Lupus Erythematosus</a>&nbsp;&nbsp;<a href="https://proddocwire.wpengine.com/pulmonology/real-world-safety-and-efficacy-of-omalizumab-in-patients-with-severe-allergic-asthma-a-long-term-post-marketing-study-in-japan/">Real-world safety and efficacy of omalizumab in patients with severe allergic asthma: A long-term post-marketing study in Japan</a>&nbsp;<a href="https://proddocwire.wpengine.com/allergy-and-immunology/endotypes-of-severe-allergic-asthma-patients-who-clinically-benefit-from-anti%E2%80%90ige-therapy/">Endotypes of severe allergic asthma patients who clinically benefit from anti&#8208;IgE therapy</a>&nbsp;<a href="https://proddocwire.wpengine.com/abstracts/fatigue-systemic-lupus-erythematosus-2/">Fatigue in systemic lupus erythematosus and other autoimmune skin diseases</a>Source:&nbsp;<a href="https://onlinelibrary.wiley.com/doi/abs/10.1002/art.40828">Arthritis &amp; Rheumatology</a>

Areef Ishani, MD

Joel M. Topf, MD, FACP

Kidney Stones With Chlorthalidone Versus Hydrochlorothiazide

NKF Spring Clinical Meetings 2025

MarkAlain Déry, DO

Eric Griggs, MD

Measles in America: An Ongoing Problem

Infectious Disease

Roger Rodby, MD

Seldin Award Winner Advocates Online Education

Latest News

Omalizumab Safe and Effective in SLE Patients

Rheumatology

Researchers recently tested the effects of omalizumab in patients with systemic lupus erythematosus (SLE) and had positive initial results.  ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe